Cost Estimation of Point of Care B-Type Natriuretic Peptide for the Diagnosis of Heart Failure in the Emergency Department - Application to Alberta

• Author(s) / Creator(s)

  • Chuck, Anderson
  • Collins, Seana
  • Jacobs, Philip

• The aim of this report is to provide a cost estimate, over a one year time period from a payer’s perspective, of Biosite Triage Point-of-Care (POC) B-Type Natriuretic Peptide (BNP) assay used to rule out congestive heart failure (CHF) from other pulmonary conditions for patients presenting in Alberta emergency departments with acute dyspnea, but who do not have acute mycardial infarction (AMI), renal dysfunction (RD), or unstable angina (UA). The scope of this report is limited to the use of BNP for diagnosis and does not address prognosis, management, or patient monitoring.

• Date created

  2005-05-30

• Subjects / Keywords

  • Congestive Heart Failure -Diagnostic Methods - Economic Reports

• Type of Item

  Report

• DOI

  https://doi.org/10.7939/R30Z71B1J

• License

  Attribution-NonCommercial-NoDerivatives 4.0 International